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Niels S. Vermeer1,*, Thijs J. Giezen2, Sofia Zastavnik3, Elena Wolff-Holz4 and Ana Hidalgo-Simon3
Biologicals are established treatment options that require pharmacovigilance adapted to their specific nature, 
including the need for products to be identifiable up to the specific manufacturer in reports of adverse drug reactions 
(ADRs). This study explored the identifiability of 10 classes of similar and related biologicals up to the level of the 
manufacturer in ADR reports received from European clinical practice between 2011 and June 2016. Adequate 
identifiers were reported for 96.7% of the suspected biologicals, ranging from 89.5% for filgrastim to 99.8% for 
interferon beta- 1a. The product identifiability remained consistently high over time for classes of biologicals for 
which biosimilars were introduced during follow- up. The overall batch traceability was, however, only ensured for 
20.5% of the suspected biologicals and needs further improvement. This study shows that the European system for 
identification of ADRs to the level of the manufacturer is robust, allowing for the timely detection of potential 
product- specific safety signals for biologicals.
Biological medicinal products, also called biologicals or biologics, 
are important treatment options for a variety of chronic and life- 
threatening diseases. As compared with traditional chemically 
synthesized medicines, biologicals have specific characteristics, in-
cluding, among others, a complex manufacturing process, limited 
predictability of preclinical to clinical data, and a high potential 
for immunogenicity.1 For biologicals, as for all drugs, pharma-
covigilance plays an important role in the discovery, detection, and 
characterization of adverse drug reactions (ADRs) in the postmar-
keting setting due to the inherent limitations of clinical trials (e.g., 
a homogenous population, a relatively low sample size and time 
window, and limited use of concomitant medication).2 Perceived 
challenges in the pharmacovigilance of biologicals are the identi-
fiability (identification of the product responsible for the ADR) 
and traceability (identification of the product and the batch num-
ber responsible for the ADR), particularly in those cases in which 
more than one medicine with the same generic name, the so- called 
international nonproprietary name (INN), exists on the market.3 
Other challenges include immunogenicity studies, manufacturing 
variability, stability, and cold chain, and are laid down in the reg-
ulatory guidance document “Good Pharmacovigilance Practices 
for biological medicinal products.”4
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Adverse drug reactions (ADRs) to biologicals may be 
product- specific or batch- specific, resulting from changes 
in manufacturing. Due to the increased availability and use 
of biosimilars in Europe, the product identifiability up 
to the manufacturer in ADR reports has received 
scrutiny.
WHAT QUESTION DID THIS STUDY ADDRESS?
 We investigated the product identifiability in ADR reports 
received from European clinical practice between 2011 and 
2016. We focused on classes of biologicals for which similar 
or related (bearing the same generic name) products are 
available.
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
 We show that product identifiers are available for 96.7% of 
the suspected biologicals in ADR reports. The identifiability 
remained robust over time for biologicals for which biosimilars 
were introduced. Traceability of individual batches was identi-
fied as an area for improvement.
HOW MIGHT THIS CHANGE CLINICAL PHARMA­
COLOGY OR TRANSLATIONAL SCIENCE?
 The high level of product identification is reassuring, and 
confirms that product- specific safety signals can be timely iden-
tified in multisource markets with multiple similar and related 
biologicals. Fears of poor product identification when switch-
ing between products are not justified.
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With the expiration of regulatory data protection of several bi-
ologicals, biosimilars, or follow- on biologics, have been approved 
by the regulatory agencies. Nearly 50 biosimilars have been ap-
proved by the European Medicines Agency (EMA) for 14 differ-
ent active substances.5 A biosimilar is a medicine highly similar 
to another already marketed biological medicinal product, the 
so- called “reference medicine” (see definitions in Box 1). As the 
manufacturing process of a biological is owned by a pharmaceuti-
cal company, the company developing a biosimilar should establish 
its own production process and show that its finished product is 
similar to the reference medicine. Biosimilars are extensively being 
evaluated and compared with the reference product but some dif-
ferences between the biosimilar and the reference product might 
exist with regard to some minor quality attributes, for example, 
in the glycosylation pattern of the protein. The pharmaceutical 
company developing the biosimilar should ensure that these dif-
ferences do not have an impact on clinical efficacy and safety.6,7 
The ability to identify the product, biosimilar, or reference prod-
uct responsible for a certain adverse event is important in phar-
macovigilance. This need is regularly highlighted by organizations 
representing healthcare professionals and patients.7 A previous 
study in EudraVigilance, the European database for collection 
of suspected ADR reports, showed that the identifiability up to 
the product level was 96.2% over the period 2004–2010 for the 
groups of biologicals for which a biosimilar was approved in the 
European Union (EU), whereas traceability by batch number was 
only 21.1% and requires improvement.8
Biosimilars are approved based on a scientifically tailored 
data package, which consists of extensive comparability stud-
ies between the biosimilar and the reference product.9 On 
the other hand, pharmaceutical companies have been de-
veloping the so- called related biological products for a long 
time. Related biological products are defined as products that 
contain the same or closely related active substance as an-
other authorized biological medicine and carry the same 
INN (see Box 1). Examples include different interferon be-
ta- 1a–containing products (Rebif, Merck Europe, Amsterdam, 
the Netherlands, and Avonex, Biogen, Badhoevedorp, the 
Netherlands) and different factor VIII–containing products. 
The safety profile among these “related” products may poten-
tially differ, as they have been developed on the basis of inde-
pendent studies, without the inherent need to show similarity 
to any reference product. A difference in the safety profile can 
be illustrated by the above- mentioned products containing in-
terferon beta- 1a, Rebif, which is approved for subcutaneous 
use, whereas Avonex is approved for intramuscular administra-
tion. A direct comparison showed that injection- site reactions, 
asymptomatic abnormalities of liver enzymes, altered leucocyte 
counts, and development of neutralizing antibodies occurred 
more frequently in the patients treated with Rebif as compared 
to Avonex.10 In addition, a safety signal for Rebif was investi-
gated after an unexpected increase in cases of thrombotic mi-
croangiopathy was observed for this product following a change 
in the formulation process.11 These examples underline the 
importance of being able to clearly identify related biological 
products that carry the same INN and may present potential 
differences in their safety profiles.
After medicines are placed on the market and during their 
commercial life, companies are likely to improve or upscale pro-
cesses and/or make changes to the formulation of the end prod-
uct. These changes always need to be assessed and approved by 
the regulatory agencies. In addition, production processes can be 
complex, often consisting of multiple steps that can potentially 
influence the characteristics of the end product at every single 
step of the production cascade. Thus, the pharmaceutical com-
pany should ensure that their production process is stable and 
robust to prevent relevant differences between different batches 
of the end product.12,13 Identification of the batch responsible for 
an adverse event (traceability) is important in this context for all 
biologicals.
Since the previous EudraVigilance study, which included data up 
to 2010, a considerable number of biosimilars have been approved 
in Europe and their use in clinical practice has increased substan-
tially. In addition, related biologicals are an important category to 
take into consideration from a pharmacovigilance perspective. This 
study, therefore, aims to assess the level of precise identification of 
biologicals down to the product level for biologicals for which a 
biosimilar or a related product has been approved, in reports of sus-
pected ADRs received from European clinical practice.
Box 1  Definitions of similar and related biologicals
Biological medicinal product: A medicinal product 
that contains an active substance that is produced by 
or extracted from a biological source and that needs 
for its characterization and the determination of its 
quality a combination of physiochemical- biological 
testing, together with the production process and its 
control.35
Biosimilar: A biological medicinal product highly simi-
lar to another biological medicine already marketed in 
the European Union (the so- called “reference medi-
cine”), in terms of physical, chemical, and biological 
properties. There may be minor differences from the 
reference medicine that are not clinically meaningful 
in terms of safety or efficacy. Biosimilars are approved 
on the basis of a scientifically tailored data package, 
often relying on some clinical data obtained with the 
reference medicine. Companies can market approved 
biosimilars once the period of market protection of 
the reference medicine expires (after 10 years).9
Related biological product: A medicinal product that 
contains the same or a closely related active sub-
stance (based on the international nonproprietary 
name) as (an)other authorized biological medicine. 
These products are approved on the basis of a full 
application dossier and not as a biosimilar.4
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RESULTS
Overall, a total of 49,003 ADR reports related to 10 classes of bi-
ologicals for which similar or related products have been approved 
in Europe were retrieved from EudraVigilance. The reports had 
been received from European clinical practice between January 
2011 and June 2016. As shown in Figure 1, the included reports 
reported a total of 61,263 biologicals, corresponding to a median 
of 1 (range: 1–84) biological per ADR report. Among the reported 
biologicals, 52,591 were categorized by the reporter as “suspected” 
to have caused or contributed to the reported ADR (hereafter re-
ferred to as “suspected biologicals”), and the remaining biologicals 
were categorized by the reporter as either concomitant (not sus-
pected to have contributed to the ADR) or interacting (subject of a 
suspected interaction) medications. The most frequently reported 
suspected biologicals involved etanercept (n = 19,716) and inflix-
imab (n = 12,045), followed by human normal immunoglobulins 
(n = 9,130), and interferon beta- 1a (n = 4,573).
As shown in Table 1, most of the ADR reports had been re-
ceived from reporters in France (9,145; 18.7%), the United 
Kingdom (8,592; 17.5%), and Germany (7,569; 15.5%). Overall, 
25% (n = 12,266) of all ADR reports included in the present study 
were received directly from patients, without any medical confir-
mation by a healthcare professional, and the remaining 75% was re-
ceived either directly from patients with subsequent confirmation 
by a healthcare professional or directly received from a healthcare 
professional.
The identifiability of the reported biologicals was first as-
sessed along the information reported in the designated fields 
for drug identification in ADR reports. The overall identifiabil-
ity was 96.7% (50,833 of 52,591) for suspected biologicals, and 
86.3% (7,484 of 8,672) for biologicals that had been categorized 
as concomitant or interacting medications. Interestingly, the 
identifiability of suspected biologicals was higher in ADR re-
ports received directly from patients (99.3%; 12,611 of 12,695 
suspected biologicals) than in reports received from healthcare 
professionals (95.8%; 38,073 of 39,746 suspected biologicals). As 
shown in Table 2, the identifiability differed between the classes 
of biologicals, ranging from 89.5% for suspected filgrastim- 
containing products up to 99.8% for suspected interferon beta- 
1a- containing products.
For the 2,946 biologicals reported as suspected, concomitant, 
or interacting (pertaining to 2,635 ADR reports) that were not 
identifiable based on the information in the designated fields for 
drug identification, the narrative and reporter’s comments were 
retrieved from EudraVigilance (available for 2,059 of the 2,635 
ADR reports) and explored for further drug identifying infor-
mation. Overall, for an additional 393 (of which 281 suspected) 
reported biologicals adequate drug identifiers were retrieved by 
this search strategy. The identifiability of suspected biologicals 
hereby increased to 97.2% (51,114 of 52,591), as further shown 
in Table 2.
Although the main aim of this study was to explore the level 
of identification of biologicals down to the marketed product 
name, we also explored the traceability up the batch level for the 
reports biologicals. The overall batch traceability was ensured 
for 20.5% of the suspected biologicals, and varied widely from 
1.8% (8 of 448) for follitropin alfa- containing products up to 
69.3% (6,326 of 9,130) for human normal immunoglobulin- 
containing products (not shown in table). No clear trend was 
observed in reporting of batch numbers for traceability purposes 
over time. The overall batch traceability was ensured for 29.3% 
of the suspected biologicals in 2011, 11.4% in 2012, 16.3% in 
2013, 21.0% in 2014, 21.7% in 2015, and 23.5% in 2016 (up to 
June 30, 2016).
Figure 1 Adverse drug reaction (ADR) reports retrieved from EudraVigilance. IG, immunoglobulin.
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To assess whether the reporting of drug identifying informa-
tion changed after the introduction of the first biosimilar prod-
uct, the identifiability was compared for two exemplary product 
classes: infliximab- containing and insulin glargine–containing 
products were compared prior to and after the introduction 
of the first biosimilar (September 2013 and September 2014, 
respectively). In both classes, there has been considerable mar-
keting experience since the introduction of the first biosimilar, 
although their vastly different contexts of use—from primarily 
home- care settings (insulin glargine) to hospital care (inflix-
imab)—may have an impact on the recording and reporting of 
drug identifying information. As shown in Figure 2, the product 
identifiability remained consistently robust over time for both 
product classes.
DISCUSSION
This study shows that product identifiers were reported for 96.7% 
of the biologicals reported as suspected in ADR reports received 
from European clinical practice between 2011 and June 2016. 
This is in line with the results from earlier studies in European,8 
Italian,14 and US15 pharmacovigilance databases, which showed 
robust levels of product identification for classes of biologicals for 
which similar products are available. The current study also found 
that the product identifiability remained consistently high over 
time for those classes of biologicals for which biosimilars were in-
troduced during the study period. Due to the increasing availabil-
ity and use of biosimilars in European clinical practice over the past 
few years, with now circa 50 biosimilars having received regulatory 
approval, adequate product identifiability has become increasingly 
important. The findings from the current study are reassuring, 
showing that identification of ADRs to the product level is robust, 
thereby ensuring that safety signals for biologicals can be detected 
and related to a specific product in a timely manner.
As already illustrated in the introduction by the case of inter-
feron beta- 1a, related biological products are approved based on 
conventional data package, and differences with regard to safety 
and efficacy between these products might exist.10 Early detection 
of potential safety signals and the ability to relate a potential safety 
signal to a specific brand name is of high importance for regulators 
to act in a timely manner to ensure safe and efficacious use of these 
agents in clinical practice. This study supports that the current sys-
tem of reporting is robust and reliable to identify the product.
In contrast to related biological products, the regulatory path-
way for approval of a biosimilar is a thorough comparability exer-
cise, in which similarity needs to be shown to the reference product 
at the level of quality, safety, and efficacy.6 In the current climate 
of cost- savings and concerns regarding the price of effective but 
expensive biological therapies for chronic and life- threatening 
conditions, there is high interest in the introduction of biosimi-
lar medicines. It is expected that the introduction of biosimilars 
will lead to cost reduction and that a larger proportion of patients 
Table 1 Characteristics of the ADR reports (n = 49,003) 
included in the present study
Number of ADR reports, proportion 
of total
Year of receipt
2011 8,191 16.7%
2012 9,214 18.8%
2013 9,126 18.6%
2014 8,101 16.5%
2015 9,509 19.4%
2016 (up to June 30) 4,862 09.9%
Primary receiver
Pharmaceutical company 28,997 59.2%
Regulatory authority 20,006 40.8%
Reporter type
Healthcare professionala 36,580 74.6%
Patient 12,266 25.0%
Unknown 157 00.3%
Reporter country
France 9,145 18.7%
United Kingdom 8,592 17.5%
Germany 7,596 15.5%
Italy 5,786 11.8%
The Netherlands 4,714 09.6%
Spain 2,250 04.6%
Sweden 2,026 04.1%
Other countries 8,894 18.1%
ADR, adverse drug reaction.
aCases for which reports had been received from both a patient as well as a 
healthcare professional were classified as healthcare professional cases.
Table 2 Product identifiability of suspected similar and 
related biologicals in spontaneous reports received from 
European clinical practice between 2011 and June 30, 2016
Product, totals 
(n)
Identifiable 
product
Identifiable 
product, including 
narrative search
n % n %
Similar biologicals
Etanercept 19,716 19,012 96.4% 19,167 97.2%
Infliximab 12,045 11,342 94.2% 11,395 94.6%
Insulin 
glargine
2,446 2,364 96.6% 2,381 97.3%
Filgrastim 1,043 934 89.5% 944 90.5%
Epoetin alfa 1,084 1,045 96.4% 1,056 97.4%
Somatropin 1,047 1,007 96.2% 1,023 97.7%
Follitropin 
alfa
448 442 98.7% 442 98.7%
Related biologicals
Human 
normal IG
9,130 9,070 98.7% 9,086 99.5%
Interferon 
beta- 1a
4,573 4,562 99.8% 4,564 99.8%
Octocog alfa 1,059 1,055 99.6% 1,056 99.7%
Overall 52,591 50,833 96.7% 51,114 97.2%
IG, immunoglobulin.
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could benefit from these treatments.16 Lack of understanding 
around how biosimilars are developed and approved have led some 
patients and practitioners groups to voice some distrust regarding 
biosimilars, although positions are evolving as knowledge of bio-
similars increases. An often-heard argument regarding use of bi-
osimilars is the potential lack of clear identification of suspected 
drugs, increased when multiple switches occur.17–19 This study 
has, however, shown that identifiability up to the product level for 
classes of biologicals for which similar products are marketed is 
high in EudraVigilance.
Identification of the batch number (traceability), however, 
showed low levels of overall compliance in this study: for 20.5% 
of the suspected biologicals a batch number was reported. The 
requirement for batch traceability applies to all biologicals, 
including originator biological medicines, related biologics, 
and biosimilars due to the inherent batch- to- batch variabil-
ity and manufacturing changes products undergo during their 
 lifecycle.12,13 The results from the current study on batch trace-
ability are in line with a previous study in EudraVigilance, in 
which batch numbers were available for 21.1% of all suspected 
biologicals reported between 2004 and 2010.8 Due to the low 
availability of batch numbers in ADR reports, a safety issue 
from a change in an individual product might be difficult to 
link to a specific manufacturing process. The reason for the low 
batch reporting has previously been shown to be multifaceted 
and relates, among others, to inadequate recording of batch 
Figure 2 Trends in identifiability for infliximab (top) and insulin glargine (bottom) before and after introduction of its first biosimilar.
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information in pharmacy dispensing and/or medical records, un-
availability of the recorded information to the reporter at time of 
reporting, and unawareness regarding the need to report batch 
information in ADR reports.3,20,21 Efforts to improve traceabil-
ity, therefore, requires a multifaceted approach, focusing both 
on ensuring the routine recording of exposure information in 
clinical practice, as well as enabling and encouraging health-
care professionals and patients to report the required exposure 
information.3,22
The newly developed guideline on good pharmacovigilance 
practices (GVPs) for biological medicinal products contains de-
tailed guidance on measures that can be taken to ensure batch 
traceability when implementing pharmacovigilance for biolog-
icals.4 The GVP module entered into force in August 2016 and 
is a deliverable from the 2012 EU pharmacovigilance legislation, 
which contains a specific provision on traceability of biologicals 
in ADR reports.23 In the current study, no effect was yet observed 
from the 2012 pharmacovigilance legislation, as demonstrated by 
the findings that the overall batch traceability was in line with the 
results from the previous EudraVigilance study and that no clear 
trend over time could be observed in the current study. Future 
regulatory science studies may, therefore, be helpful to explore the 
impact of the GVP on batch traceability and help to identify best 
practice to improve traceability.
The 10 different classes of similar and related biologicals in-
cluded in this study differ widely in their clinical context of use 
including frequency of dosing, duration of use, extent of clini-
cal monitoring, and place of administration (hospital setting vs. 
home care), which factors have previously been linked to differ-
ences in quality of ADR reporting.24 Despite these differences, 
no major differences were observed in product identifiability 
among the different classes of biologicals in this study. The batch 
traceability, however, did differ from 1.8% for follitropin alfa up 
to 69.3% for human normal immunoglobulins. The high level of 
batch reporting compliance for the latter group relates to the fact 
that immunoglobulins have historically been regarded as blood 
products in several countries, and specific traceability require-
ments apply.3
Nomenclature of biologicals remains a subject of debate among 
some authors and has been suggested as a potential solution to 
improve traceability.19 However, differences in nomenclature will 
mainly relate to identifiability. Different regions of the world are 
considering different options,17 including the addition of suffixes 
and addition of a string of letters and numbers attached to the 
INN to differentiate medicines and improve identifiability. The 
US Food and Drug Administration has opted to introduce suf-
fixes.25 The World Health Organization has also explored the in-
troduction of a biological qualifier.19 In Europe, the identification 
of products using their unique commercial name has the major ad-
vantage of simplicity, and reinforces the approach taken by EU reg-
ulators that, although related biologicals might not have the same 
safety profile, biosimilars approved in the EU are equally effective, 
safe, and of equivalent quality with originators.7
Although product identification is essential biological phar-
macovigilance, adequate exposure ascertainment is a challenge in 
pharmacovigilance in general. For small- molecule drugs there have, 
for example, been a number of high-profile product- specific inci-
dents in the past, including intestinal perforation with a specific 
formulation of indomethacin26 and differences in cardiovascular 
risk between Spiriva Respimat and Spiriva Handihaler.27 Product- 
specific exposure is equally important for the adequate identifi-
cation and characterization of such formulation- specific safety 
signals for small- molecule drugs.
Regarding the geographic origin of reports, we limited our study 
to those originating in the European Union, as it is the region with 
more complete presence in the EudraVigilance database.28,29 This 
limits the validity of the analysis to Europe but presents the picture 
of the area of the world where most biosimilars have been approved 
and are marketed. The uptake of biosimilars in the European Union 
is regionally and nationally uneven, but it is clearly on the rise.30 
Another potential limitation resides in the period of time chosen 
for the study. We took our initial time point from the upper limit 
of the previous study in EudraVigilance.8 The cutoff point ( June 
2016) allowed us to include a large number of reports of nearly 
50,000, which makes a representative sample. It is expected that a 
longer follow- up will not have an impact on our findings. Any po-
tential misclassification of products (ADRs belonging to biosimi-
lars or related biologicals that are erroneously attributed to another 
biological with the same INN), should also be considered in the 
context of our results. This is very difficult to quantify, but a previ-
ous simulation study in which the effect of exposure misclassifica-
tion was evaluated in three test cases representing product- specific 
ADRs showed that low levels of exposure misclassification gener-
ally do not result in a delayed detection of product- specific risks.31
Considering the good identification levels demonstrated by this 
study, we can conclude that the system of identification of ADRs 
to the product level is robust: in the event of a safety signal con-
cerning a biological medicine, the identification of the specific 
product responsible should be feasible in a very high proportion of 
ADRs in the EudraVigilance database.
METHODS
The identifiability and traceability of biologicals was explored in 
spontaneous reports of suspected ADRs received from clinical practice 
across Europe between January 2011 and June 2016. The reports were 
identified from EudraVigilance, the European database for collection of 
ADR reports.
Data setting
EudraVigilance was established in 2001 by the EMA to collect reports 
of serious suspected ADRs to medicines licensed within the European 
Economic Area (EEA) and reports of any suspected transmission via 
a medicinal product of any infectious agents within the EEA. Serious 
unexpected ADRs occurring outside the EEA are also collected in 
EudraVigilance. Reporting was extended in 2004 to include suspected 
unexpected serious adverse reactions to medicines involved in clinical 
trials in the EEA and further extended in 2012 to include all serious ADRs 
outside the EEA and reports from nonhealthcare professionals. ADR 
reports in EudraVigilance are received indirectly through EU national 
competent authorities and pharmaceutical companies.
Handling of duplicate reports. Duplicate reports are routinely 
detected and handled according to a predefined algorithm as described 
in the EMA guideline on duplicate reports.32 No further deduplication 
steps were undertaken for the current study.
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Data extraction
The following ADR reports were retrieved from EudraVigilance: All indi-
vidual case safety reports received as spontaneous reports from a reporter 
within the EEA between January 1, 2011, and June 30, 2016, and in which 
at least one of the reported medicinal products involves a biological for 
which a biosimilar or related product has been approved in the EEA (see 
Table S1). Literature reports and reports received from lawyers in context 
of a litigation were not included in the current study, due to their specific 
characteristics.
Data classification and outcome definition
Product identifiability. The product identifiability—that is, the 
extent to which a single reported product is identifiable up to the 
specific manufacturer—was determined for each reported biological. 
Products were considered identifiable if any of the following 
information was available: (i) the product trade name, (ii) the name of 
active substance (INN) plus the name of the marketing authorization 
holder (MAH), or (iii) when the active substance epoetin zeta was 
reported, because this INN is specific to a biosimilar of epoetin alfa 
(from a single manufacturer) and can, therefore, be distinguished 
from the reference medicinal product. The list of product trade names 
that was used to assess the identifiability (see Table S2) was compiled 
from Micromedex (international edition, www.micromedexsolutions.
com) and the EMA’s website (www.ema.europa.eu).
The identifiability was first determined along the information con-
tained within the designated E2B fields for drug identification in ADR 
reports: proprietary medicinal product name (E2B field b.4.k.2.1), active 
substance name (E2B field b.4.k.2.2), and/or name of the MAH (E2B 
field b.4.k.4.3). E2B has been developed as a guideline to standardize the 
data elements of ADR reports and provides the basis for the electronic 
transmission of ADR reports in Europe and several other regions in the 
world including the United States.33 Further detailed guidance on the 
management and reporting of ADR reports in Europe is provided in the 
respective guidelines on GVPs.34 The GVP requires that, with regard 
to data, element B.4.k.2.1. should be populated with the proprietary/
branded medicinal product name as reported by the primary source. Two 
researchers (N.V. and A.H.) independently assessed the identifiability 
along the reported information on an aggregated level. Any inconsisten-
cies in assessment between the researchers were resolved by consensus.
As a second step, for products that were nonidentifiable based on the 
information in the designated fields for drug identification, the case nar-
rative plus the sender’s and reporter’s comments were retrieved from 
EudraVigilance. The case narratives and comments were scrutinized for fur-
ther drug-identifying information by running text searches for the product 
trade names. The search strategy was validated by two researchers (N.V. and 
A.H.) who reviewed all narratives for which the text search indicated a trade 
name was reported and by manually reviewing a 10% random sample of the 
case narratives for which the search indicated no trade name was reported.
Assessment of batch traceability. All verbatim data provided 
in the designated field for batch numbers of at least three characters was 
considered to be a batch number. To validate whether the verbatim 
data did not contain any information referring to the unavailability of 
a batch number (e.g. “don’t know” or “discarded package”), data were 
aggregated and reviewed by two researchers (N.V. and A.H.). Any 
inconsistencies in assessment between the researchers were resolved by 
consensus. No additional narrative search was performed to assess the 
batch traceability.
Primary source information. The primary reporting source was 
categorized as either healthcare professional (physician, pharmacist, 
or other health professional) or patient/nonhealthcare professional. 
Cases for which information was received both from a healthcare 
professional and a patient were categorized as healthcare professional 
cases, as these are regarded as healthcare professional–confirmed 
cases. Furthermore, the primary receivers were categorized as either 
competent authorities or marketing authorization holders.
Data analysis
The number and percentage of precise product identification and trace-
ability was calculated for all reported biologicals, and stratified according 
to the biological category (similar or related biological product), the prod-
uct class, and the drug role code (suspected/concomitant or interacting).
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